Acurx Pharmaceuticals, Inc. (ACXP) vs Liminatus Pharma, Inc. Class A Common Stock (LIMN)
A side-by-side comparison of Acurx Pharmaceuticals, Inc. and Liminatus Pharma, Inc. Class A Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACXP
Acurx Pharmaceuticals, Inc.
$1.29HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$3.87HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT
Total return — ACXP vs LIMN
growth of $100 · dividends reinvested · last 1yACXP -83.8% (-83.8%/yr)LIMN -98.4% (-98.4%/yr)ACXP compounded faster over this window
Log scale — wide-divergence pair
ACXP LIMN
ACXP vs LIMN: by the numbers
- •ACXP is the larger company ($6M vs $5M market cap).
Metrics side by side
Valuation
| Metric | ACXP | LIMN |
|---|---|---|
| P/B ratio | 0.68 | 17.29 |
Profitability
| Metric | ACXP | LIMN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -92.08% | -4165.92% |
| ROIC | -94.08% | -225.12% |
Growth (annualized)
| Metric | ACXP | LIMN |
|---|---|---|
| Total return CAGR (5Y) | -57.41% | N/A |
Go deeper
Dig into the metrics
Acurx Pharmaceuticals ROELiminatus Pharma, Inc. Class A Common Stock ROEAcurx Pharmaceuticals operating marginLiminatus Pharma, Inc. Class A Common Stock operating marginAcurx Pharmaceuticals revenue growthLiminatus Pharma, Inc. Class A Common Stock revenue growthAcurx Pharmaceuticals free cash flowLiminatus Pharma, Inc. Class A Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.